Abbott announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which… read more.
Abbott announced that the FDA has approved a change to its label that will help patients who receive a HeartMate 3 left ventricular assist device (LVAD, or heart… read more.
The American Diabetes Association® (ADA) and Abbott recently announced a collaboration to better understand the nutritional needs of people living with diabetes, obesity, and metabolic dysfunction and how… read more.
Medtronic plc announced the FDA approval for its Simplera continuous glucose monitor (CGM) — the company’s first disposable, all-in-one CGM that’s half the size of previous Medtronic CGMs…. read more.
Abbott announced it has received CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the world’s first dual chamber leadless pacemaker that treats people… read more.
Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO) . This happens when… read more.
The HeartMate Touch Communication System monitors patients who have an implantable HeartMate 3 Left Ventricular Assist Device. The HeartMate Touch Communication System works with the HeartMate System Controller…. read more.
Abbott announced that it received approval from the FDA to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming,… read more.
Abbott and Tandem Diabetes Care, Inc. a leading insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated… read more.
Abbott announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease . Data include findings from the… read more.
Abbott is initiating a US market withdrawal for the Trifecta family of valves and will be removing the limited remaining inventory from the field. On February 27, 2023,… read more.
Surmodics, Inc. announced the receipt of FDA approval for the SurVeil drug-coated balloon (DCB). The SurVeil DCB may now be marketed and sold in the U.S. to physicians… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
